Bevacizumab vs ranibizumab - An appraisal of the evidence from CATT and IVAN

Eye (Basingstoke)

Volumn 27, Issue 3, 2013, Pages 289-290

  Ahfat, F G ^a   Zaidi, F H ^a  

^a MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; PLATINUM; RANIBIZUMAB; TAXANE DERIVATIVE;

ACCIDENT; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; EDITORIAL; HEART PALPITATION; HUMAN; HYPERTENSION; INFECTION; NAUSEA; RETINAL THICKNESS; SIDE EFFECT; VISUAL ACUITY; VOMITING;

EID: 84875159572     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.1     Document Type: Editorial

References (15)

1. The IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411.
2. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration two-year results. Ophthalmology 2012; 119: 1388-1398.
3. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 2011; 305: 487-494.
4. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215-1218.
5. Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol 2012; 153: 307-313.
6. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193. (Pubitemid 46178407)
7. Levy A, Albiges-Sauvin L, Massard C, Izzedine H, Edhery S, Bahleda R et al. Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase 1 trials. Invest New Drugs 2012; 30: 1116-1120.
8. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-360.
10. Oxman AD. Subgroup analyses: The devil is in the interpretation. BMJ 2012; 344: E2022.
11. Counsell CE, Clarke MJ, Slattery J, Sandercock PA. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? BMJ 1994; 309: 1677-1681.
12. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764-1769. (Pubitemid 23355549)
13. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116: 1731-1739.
14. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN Study. Ophthalmology 2011; 118: 663-671.
15. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009; 116: 362.